BioUtah president & CEO, Kelvyn Cullimoire, was invited by the Korean Health Industry Development Institute (KHIDI), an agency of the Korean Ministry of Health, to present at the Medical Korea conference on March 19-20, 2026. The topic of Cullimore’s presentation was “Why Utah is a preferred landing place for Korean medical device companies desiring to […]

BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.

Biotech is playing an increasingly important role in U.S. economic competitiveness and national security, and Utah plays a key role in contributing to the strength of the American biotech ecosystem.

The addition of APEXecm reflects Kolosis’s continued commitment to developing and commercializing best-in-class solutions for the surgical community

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

For Fabry patients, a potential path to converting 130 clinic visits into one treatment every five years.